Bioamber Inc (NYSE:BIOA) Director Kenneth W. Wall bought 40,000 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were bought at an average cost of $0.43 per share, for a total transaction of $17,200.00. Following the completion of the transaction, the director now directly owns 170,443 shares of the company’s stock, valued at $73,290.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Bioamber Inc (NYSE BIOA) traded down $0.03 during trading on Thursday, hitting $0.39. The stock had a trading volume of 1,167,987 shares, compared to its average volume of 946,754. The company has a current ratio of 1.08, a quick ratio of 0.75 and a debt-to-equity ratio of 0.24. Bioamber Inc has a 12 month low of $0.32 and a 12 month high of $6.24.
BIOA has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Bioamber in a research report on Wednesday, November 8th. Cowen reaffirmed a “hold” rating and set a $1.00 target price on shares of Bioamber in a research report on Friday, November 10th. Finally, ValuEngine lowered Bioamber from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $6.50.
Institutional investors have recently made changes to their positions in the company. FMR LLC raised its position in Bioamber by 1.9% during the second quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock valued at $3,495,000 after buying an additional 25,000 shares during the period. Vanguard Group Inc. raised its position in Bioamber by 9.9% during the second quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 27,278 shares during the period. Bank of New York Mellon Corp raised its position in Bioamber by 336.2% during the second quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 41,701 shares during the period. TD Asset Management Inc. acquired a new position in Bioamber during the second quarter valued at $977,000. Finally, Robecosam AG raised its position in Bioamber by 82.9% during the third quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock valued at $741,000 after buying an additional 670,000 shares during the period. 29.97% of the stock is currently owned by institutional investors.
Bioamber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Ratings for Bioamber Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber Inc and related companies with MarketBeat.com's FREE daily email newsletter.